Controversial Alzheimer's drug Aduhelm to be discontinued by Biogen
The rocky road that the Alzheimer’s drug Aduhelm experienced on its way to FDA approval was considered a hard-fought victory by proponents, but skeptics and critics may feel redeemed as Biogen announced Jan. 31 that it will discontinue production and research of the controversial drug. Biogen’s announcement to abandon Aduhelm comes just two and a half years after the drug received accelerated…
View On WordPress















